{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-025945","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2022-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.910807+00:00","generated_at":"2026-06-24T15:38:08.818223+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Innoviva sells 15% TRC stake to Royalty Pharma for ~$282M upfront plus $50M milestone","bullets":["Upfront cash payment of $282M; potential $50M sales-based milestone payment.","Retained full ownership of TRC's investments in InCarda, ImaginAb, Gate Neurosciences, and Nanolive SA.","Retained royalty rights on ANORO ELLIPTA and RELVAR/BREO ELLIPTA after closing.","Theravance Biopharma concurrently selling its 85% TRC stake to Royalty Pharma.","Transaction expected to close July 2022; includes amendments to GSK collaboration agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-025945","json":"https://secwatch.observer/filing/0001140361-22-025945.json","markdown":"https://secwatch.observer/filing/0001140361-22-025945.md","text":"https://secwatch.observer/filing/0001140361-22-025945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000114036122025945/0001140361-22-025945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000114036122025945/ny20004305x24_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T15:38:08.818223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}